[go: up one dir, main page]

MX2025008750A - 5-meo-dmt for use in the treatment of postpartum depression - Google Patents

5-meo-dmt for use in the treatment of postpartum depression

Info

Publication number
MX2025008750A
MX2025008750A MX2025008750A MX2025008750A MX2025008750A MX 2025008750 A MX2025008750 A MX 2025008750A MX 2025008750 A MX2025008750 A MX 2025008750A MX 2025008750 A MX2025008750 A MX 2025008750A MX 2025008750 A MX2025008750 A MX 2025008750A
Authority
MX
Mexico
Prior art keywords
dmt
meo
treatment
postpartum depression
postpartum
Prior art date
Application number
MX2025008750A
Other languages
Spanish (es)
Inventor
Theis Terwey
Conor Burke
Naoise Gaffney
Original Assignee
Gh Res Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2023/057885 external-priority patent/WO2023186837A1/en
Priority claimed from PCT/EP2023/076820 external-priority patent/WO2024160392A1/en
Application filed by Gh Res Ireland Limited filed Critical Gh Res Ireland Limited
Publication of MX2025008750A publication Critical patent/MX2025008750A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD) wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route.
MX2025008750A 2023-01-30 2025-07-25 5-meo-dmt for use in the treatment of postpartum depression MX2025008750A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP23153996 2023-01-30
EP23154014 2023-01-30
PCT/EP2023/057885 WO2023186837A1 (en) 2022-03-27 2023-03-27 Treatment of postnatal depression
PCT/EP2023/057874 WO2023186827A1 (en) 2022-03-27 2023-03-27 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
PCT/EP2023/076820 WO2024160392A1 (en) 2023-01-30 2023-09-27 5-meo-dmt for use in the treatment of postpartum depression

Publications (1)

Publication Number Publication Date
MX2025008750A true MX2025008750A (en) 2025-11-03

Family

ID=96878788

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2025008750A MX2025008750A (en) 2023-01-30 2025-07-25 5-meo-dmt for use in the treatment of postpartum depression
MX2025008749A MX2025008749A (en) 2023-01-30 2025-07-25 Treatment of mental disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025008749A MX2025008749A (en) 2023-01-30 2025-07-25 Treatment of mental disorders

Country Status (6)

Country Link
EP (2) EP4658371A1 (en)
KR (2) KR20250134717A (en)
CN (2) CN120813347A (en)
AU (2) AU2023427992A1 (en)
IL (2) IL322430A (en)
MX (2) MX2025008750A (en)

Also Published As

Publication number Publication date
IL322427A (en) 2025-09-01
KR20250134717A (en) 2025-09-11
AU2023427992A1 (en) 2025-09-18
AU2023428136A1 (en) 2025-09-18
MX2025008749A (en) 2025-10-01
CN120641095A (en) 2025-09-12
CN120813347A (en) 2025-10-17
KR20250138805A (en) 2025-09-22
IL322430A (en) 2025-09-01
EP4658371A1 (en) 2025-12-10
EP4658267A1 (en) 2025-12-10

Similar Documents

Publication Publication Date Title
MX2025008755A (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
TNSN07413A1 (en) Use of tfpi to treat severe bacterial infections
JP2005519080A5 (en)
RU2382646C1 (en) Method of prevention and treatment of post-operation pain syndrome in case of vast thoraco-abdominal operations
MXPA04003548A (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi).
NZ799504A (en) Use of penehyclidine in treatment or prevention of vision-impairing eye diseases
MX2024011142A (en) Treatment of cutaneous neurofibromas with mirdametinib.
MX2024005107A (en) Novel use of quinazolinone compound for the treatment of cancer.
MX2025008750A (en) 5-meo-dmt for use in the treatment of postpartum depression
DE602005009176D1 (en) TREATMENT OF T-CELL LYMPHOMIC BY 10-PROPARGYL-10-DEAZAAMINEOPTERIN
MX2015009546A (en) Increased dosage of efavirenz for the treatment of cancer.
NZ751972A (en) Treatment of prurigo nodularis
CN114616240A (en) Compositions comprising antimicrobial peptides
Buvanendran et al. Anesthetic techniques for minimally invasive total knee arthroplasty
ZA202407245B (en) Novel use of pitolisant for treating severe fatigue
MX2022011651A (en) Method for treating diabetes.
MX2025005021A (en) Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
PH12021551951A1 (en) Combination therapies for use in treating cancer
WO2022261344A8 (en) Subcutaneous formulation and methods for treating edema refractory to oral diuretics
RU2823512C2 (en) Method for combined anesthesia in bypass surgery in patients with portal hypertension
Cuthbertson Goldilocks, elephants, and surgical fluids
Goodberlet et al. Uncertainty of treatment of Serratia marcescens endocarditis
RU2014154396A (en) LIQUID MEDICINAL CONTAINING CARBON OXIDE DISSOLVED IN IT AND THE THERAPEUTIC METHOD OF USE
MX2025001118A (en) Cancer combination therapy including a bcl-2 inhibitor
Jbarat et al. Intraoperative local infiltration anesthesia effect on post-operative pain after total knee replacement